Search: id:"swepub:oai:DiVA.org:uu-319478" >
Good manufacturing ...
Good manufacturing practice production of [68Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.
-
- Velikyan, Irina (author)
- Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap,Radiologi
-
- Wennborg, Anders (author)
- Affibody AB, Solna
-
- Feldwisch, Joachim (author)
- Uppsala universitet,Medicinsk strålningsvetenskap,Affibody AB, Solna,Vladimir Tolmachev
-
show more...
-
- Lindman, Henrik (author)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Carlsson, Jörgen, 1944- (author)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
- Sörensen, Jens (author)
- Uppsala universitet,Radiologi
-
show less...
-
(creator_code:org_t)
- 2016
- 2016
- English.
-
In: American Journal of Nuclear Medicine and Molecular Imaging. - 2160-8407. ; 6:2, s. 135-153
- Related links:
-
https://urn.kb.se/re...
Abstract
Subject headings
Close
- Therapies targeting human epidermal growth factor receptor type 2 (HER2) have revolutionized breast cancer treatment, but require invasive biopsies and rigorous histopathology for optimal patient stratification. A non-invasive and quantitative diagnostic method such as positron emission tomography (PET) for the pre-therapeutic determination of the presence and density of the HER2 would significantly improve patient management efficacy and treatment cost. The essential part of the PET methodology is the production of the radiopharmaceutical in compliance with good manufacturing practice (GMP). The use of generator produced positron emitting (68)Ga radionuclide would provide worldwide accessibility of the agent. GMP compliant, reliable and highly reproducible production of [(68)Ga]Ga-ABY-025 with control over the product peptide concentration and amount of radioactivity was accomplished within one hour. Two radiopharmaceuticals were developed differing in the total peptide content and were validated independently. The specific radioactivity could be kept similar throughout the study, and it was 6-fold higher for the low peptide content radiopharmaceutical. Intrapatient comparison of the two peptide doses allowed imaging optimization. The high peptide content decreased the uptake in healthy tissue, in particular liver, improving image contrast. The later imaging time points enhanced the contrast. The combination of high peptide content radiopharmaceutical and whole-body imaging at 2 hours post injection appeared to be optimal for routine clinical use.
Keyword
- Affibody
- GMP
- Gallium-68
- HER2
- breast cancer
- clinical study
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database